Your browser doesn't support javascript.
Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation.
Bousquet, Jean; Haahtela, Tari; Blain, Hubert; Czarlewski, Wienczyslawa; Zuberbier, Torsten; Bedbrook, Anna; Cruz, Alvaro A; Fonseca, Joao A; Klimek, Ludger; Kuna, Piotr; Samolinski, Boleslaw; Valiulis, Arunas; Lemaire, Antoine; Anto, Josep M.
  • Bousquet J; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Haahtela T; University Hospital Montpellier, Montpellier, France.
  • Blain H; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany.
  • Czarlewski W; Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Zuberbier T; Department of Geriatrics, Montpellier University Hospital, MUSE, Montpellier, France.
  • Bedbrook A; MASK-air, Montpellier, France.
  • Cruz AA; Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Fonseca JA; Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany.
  • Klimek L; MASK-air, Montpellier, France.
  • Kuna P; Fundaçao ProAR, Federal University of Bahia and GARD/WHO Planning Group, Salvador, Bahia, Brazil.
  • Samolinski B; Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine, University of Porto, Porto, Portugal.
  • Valiulis A; Patient-Centred Innovation and Technologies Group (PaCeIT), Center for Health Technology and Services Research (CINTESIS), University of Porto, Porto, Portugal.
  • Lemaire A; Medicina, EDucaçao, I&D e Avaliaçao, Lda (MEDIDA), Porto, Portugal.
  • Anto JM; Imunoalergologia, CUF, Porto, Portugal.
Clin Transl Allergy ; 12(3): e12127, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1739141
ABSTRACT
Vaccination is a highly effective preventive measure against COVID-19. However, complementary treatments are needed to better control the disease. Fermented vegetables and spices, agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and TRPA1/V1 channels (Transient Receptor Potential Ankyrin 1 and Vanillin 1), may help in the control of COVID-19. Some preliminary clinical trials suggest that curcumin (spice) can prevent some of the COVID-19 symptoms. Before any conclusion can be drawn and these treatments recommended for COVID-19, the data warrant confirmation. In particular, the benefits of the foods need to be assessed in more patients, through research studies and large trials employing a double-blind, placebo-controlled design.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Clin Transl Allergy Year: 2022 Document Type: Article Affiliation country: Clt2.12127

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: Clin Transl Allergy Year: 2022 Document Type: Article Affiliation country: Clt2.12127